Verrica Pharmaceuticals Q1 2024 GAAP EPS $(0.44) Misses $(0.42) Estimate, Sales $3.826M Beat $2.777M Estimate
Portfolio Pulse from Benzinga Newsdesk
Verrica Pharmaceuticals reported its Q1 2024 earnings with a GAAP EPS of $(0.44), missing the $(0.42) estimate. However, its sales of $3.826M exceeded the $2.777M estimate.
May 13, 2024 | 11:32 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Verrica Pharmaceuticals' Q1 2024 earnings report showed a mixed performance with a miss on GAAP EPS but a beat on sales estimates.
The miss on the GAAP EPS could negatively impact investor sentiment, potentially putting downward pressure on VRCA's stock price. However, the beat on sales estimates could offset this by indicating stronger-than-expected revenue growth, which might support the stock price. The mixed results lead to a neutral short-term price direction expectation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100